The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Open accessAbstract
BACKGROUND: The therapeutic role of 6-mercaptopurine (6-MP) and azathioprine (AZA) remains controversial due to their perceived relatively slow-acting effect and adverse effects. An updated meta-analysis was performed to evaluate the efficacy of these agents for the maintenance of remission in quiescent Crohn's disease. OBJECTIVES: To assess the efficacy of AZA and 6-MP for maintenance of remission in quiescent Crohn's disease. SEARCH METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library from inception to June 30, 2015. SELECTION CRITERIA: Randomized controlled trials of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients (> 18 years) with quiescent Crohn's disease were considered for inclusion. Patients with surgically-induced remission were excluded. DATA COLLECTION AND ANALYSIS: At least two authors independently extracted data and assessed study quality using the Cochrane risk of bias tool. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (CI). The primary outcomes was maintenance of remission. Secondary outcomes included steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. All data were analyzed on an intention-to-treat basis. The overall quality of the evidence supporting the primary outcome and selected secondary outcomes was assessed using the GRADE criteria. MAIN RESULTS: Eleven studies (881 participants) were included. Comparisons included AZA versus placebo (7 studies, 532 participants), AZA or 6-MP versus mesalazine or sulfasalazine (2 studies, 166 participants), AZA versus budesonide (1 study, 77 participants), AZA and infliximab versus infliximab (1 study, 36 patients), 6-MP versus methotrexate (1 study, 31 patients), and early AZA versus conventional management (1 study, 147 participants). Two studies were rated as low risk of bias. Three studies were rated as high risk of bias for being non-blinded. Six studies were rated as unclear risk of bias. A pooled analysis of six studies (489 participants) showed that AZA (1.0 to 2.5 mg/kg/day) was significantly superior to placebo for maintenance of remission over a 6 to 18 month period. Seventy-three per cent of patients in the AZA group maintained remission compared to 62% of placebo patients (RR 1.19, 95% CI 1.05 to 1.34). The number needed to treat for an additional beneficial outcome was nine. A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (327 events) and unclear risk of bias. A pooled analysis of two studies (166 participants) showed no statistically significant difference in the proportion of patients who maintained remission between AZA (1.0 to 2.5 mg/kg/day) or 6-MP (1.0 mg/day) and mesalazine (3 g/day) sulphasalazine (0.5 g/15 kg) therapy. Sixty-nine per cent of patients in the AZA/6-MP group maintained remission compared to 67% of mesalazine/sulphasalazine patients (RR 1.09, 95% CI 0.88 to 1.34). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (113 events) and high or unclear risk of bias. One small study found AZA (2.0 to 2.5 mg/kg/day) to be superior to budesonide (6 to 9 mg/day) for maintenance of remission at one year. Seventy-six per cent (29/38) of AZA patients maintained remission compared to 46% (18/39) of budesonide patients (RR 1.65, 95% CI 1.13 to 2.42). GRADE indicated that the overall quality of the evidence supporting this outcome was low due to sparse data (47 events) and high risk of bias. One small study found no difference in maintenance of remission rates at one year between combination therapy with AZA (2.5 mg/kg) and infliximab (5 mg/kg every 8 weeks) compared to infliximab monotherapy. Eighty-one per cent (13/16) of patients in the combination therapy group maintained remission compared to 80% (16/20) of patients in the infliximab group (RR 1.02, 95% CI 0.74 to 1.40). GRADE indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (29 events) and unclear risk of bias. One small study found no difference in maintenance of remission rates at one year between 6-MP (1 mg/day) and methotrexate (10 mg/week). Fifty per cent (8/16) of 6-MP patients maintained remission at one year compared to 53% (8/15) of methotrexate patients (RR 0.94, 95% CI 0.47 to 1.85). GRADE indicated that the overall quality of the evidence supporting this outcome was very low due to very sparse data (16 events) and high risk of bias. One study (147 participants) failed to show any significant benefit for early azathioprine treatment over a conventional management strategy. In the early azathioprine treatment group 67% (11-85%) of the trimesters were spent in remission compared to 56% (29-73%) in the conventional management group. AZA when compared to placebo had significantly increased risk of adverse eve
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
A method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
Pearson, D. C., May, G. R., Fick, G. H., & Sutherland, L. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00009 · Cited by 950
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D. (2005) · Gut · doi:10.1136/gut.2004.049460 · Cited by 808
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
Fraser, A. G. (2002) · Gut · doi:10.1136/gut.50.4.485 · Cited by 629
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Self-citationA controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Keele, G. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91022-2 · Cited by 499
Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
Bouhnik, Y., Scemama, G., Taï, R., Matuchansky, C., Rambaud, J.-C., Lémann, M., Modigliani, R., & Mary, J.-Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90402-x · Cited by 466
Hanauer, S. B., Korelitz, B. I., Rutgeerts, P., Peppercorn, M. A., Thisted, R. A., Cohen, R. D., & Present, D. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.002 · Cited by 460
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
LÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Lémann, M., Mary, J.-Y., Colombel, J.-F., Duclos, B., Soule, J.-C., Lerebours, E., Modigliani, R., & Bouhnik, Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.031 · Cited by 349
DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE
O'Donoghue, D. P., Dawson, A. M., Powell-Tuck, J., Bown, R. L., & Lennard-Jones, J. E. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92524-2 · Cited by 332
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Willoughby, J. M. T., Beckett, J., Kumar, P., & Dawson, A. M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90268-6 · Cited by 314
Azathioprine for maintenance of remission in Crohn's disease
Pearson, D., May, G., Fick, G., & Sutherland, L. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067 · Cited by 304
D'Haens, G. R., Vermeire, S., Van Assche, G., Noman, M., Aerden, I., Van Olmen, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.010 · Cited by 301
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease
Ardizzone, S., Maconi, G., Sampietro, G. M., Russo, A., Radice, E., Colombo, E., Imbesi, V., Molteni, M., Danelli, P. G., Taschieri, A. M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.051 · Cited by 297
Cosnes, J., Bourrier, A., Laharie, D., Nahon, S., Bouhnik, Y., Carbonnel, F., Allez, M., Dupas, J., Reimund, J., Savoye, G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.04.048 · Cited by 268
National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
Singleton, J. W., Law, D. H., Kelley, M. L., Mekhjian, H. S., & Sturdevant, R. A. L. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90386-x · Cited by 263
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Panés, J., López–SanRomán, A., Bermejo, F., García–Sánchez, V., Esteve, M., Torres, Y., Domènech, E., Piqueras, M., Gomez–García, M., Gutiérrez, A., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.009 · Cited by 252
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety
Dubinsky, M. C. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00344-1 · Cited by 249
GEARRY, R. B., & BARCLAY, M. L. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03832.x · Cited by 236
Maté-Jiménez, J., Hermida, C., Cantero-Perona, J., & Moreno-Otero, R. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012110-00010 · Cited by 227
Savarino, E., Bodini, G., Dulbecco, P., Assandri, L., Bruzzone, L., Mazza, F., Frigo, A. C., Fazio, V., Marabotto, E., & Savarino, V. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.287 · Cited by 216
A controlled trial of azathioprine in Crohn's disease
Rosenberg, J. L., Levin, B., Wall, A. J., & Kirsner, J. B. (1975) · The American Journal of Digestive Diseases · doi:10.1007/bf01070829 · Cited by 201
Oren, R., Moshkowitz, M., Odes, S., Becker, S., Keter, D., Pomeranz, I. S., Shirin, H., Shirin, C., Reisfeld, I., Broide, E., et al. (1997) · PubMed · Cited by 200
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Rhodes, J., Beck, P., Bainton, D., & Campbell, H. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90598-8 · Cited by 184
Methotrexate for maintenance of remission in Crohn's disease
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W., & Chande, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006884.pub3 · Cited by 180
Self-citationReinisch, W., Angelberger, S., Petritsch, W., Shonova, O., Lukas, M., Bar-Meir, S., Teml, A., Schaeffeler, E., Schwab, M., Dilger, K., et al. (2010) · Gut · doi:10.1136/gut.2009.194159 · Cited by 172
Treton, X., Bouhnik, Y., Mary, J., Colombel, J., Duclos, B., Soule, J., Lerebours, E., Cosnes, J., & Lemann, M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.028 · Cited by 168
(2004) · Die Rehabilitation · doi:10.1055/s-2004-818553 · Cited by 167
Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., & Chapman, B. A. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.926 · Cited by 159
Treatment of Crohn's Disease with Azathioprine: A Controlled Evaluation
Klein, M., Binder, H. J., Mitchell, M., Aaronson, R., & Spiro, H. (1974) · Gastroenterology · doi:10.1016/s0016-5085(74)80166-6 · Cited by 158
Mantzaris, G. J., Christidou, A., Sfakianakis, M. E., Roussos, A., Koilakou, S., Petraki, K., & Polyzou, P. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20777 · Cited by 158
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Prefontaine, E., Sutherland, L. R., MacDonald, J. K., & Cepoiu‐Martin, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub2 · Cited by 155
Self-citationAzathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Chande, N., Tsoulis, D. J., & MacDonald, J. K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub4 · Cited by 121
Self-citationArmuzzi, A., Felice, C., Papa, A., Marzo, M., Pugliese, D., Andrisani, G., Federico, F., Vitis, I. D., Rapaccini, G. L., & Guidi, L. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.04.020 · Cited by 105
Korelitz, B. I., Hanauer, S., Rutgeerts, P., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)84115-2 · Cited by 103
Reinisch, W., Panés, J., Lémann, M., Schreiber, S., Feagan, B. G., Schmidt, S. L., Sturniolo, G. C., Mikhailova, T. L., Alexeeva, O., Sanna, L., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02024.x · Cited by 102
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease
Gordon, M. A., Taylor, K. N., Akobeng, A. K., & Thomas, A. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010233.pub2 · Cited by 81
VILIEN, M., Dahlerup, J. F., Munck, L. K., Nørregaard, P., Grønbæk, K., & Fallingborg, J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01944.x · Cited by 76
Mañosa, M., Cabré, E., Bernal, I., Esteve, M., García-Planella, E., Ricart, E., Peñalva, M., Cortés, X., Boix, J., Piñol, M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31828ef13f · Cited by 56
Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease
Myrelid, P., Svärm, S., Andersson, P., Almer, S. H., Bodemar, G., & Olaison, G. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520600587378 · Cited by 21
A double-blind trial of azathioprine in Crohn's disease.
Jm, W., Kumar, P., Beckett, J., & Dawson, A. M. (1971) · PubMed · Cited by 20
Endoscopic healing of Crohn's Ileo-colitis with azathioprine
Colombel, J. F., Lémann, M., Bouhnik, Y., Duclos, B., Soulé, J. C., Lerebours, É., Mary, J., & GETAID, T. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)80985-x · Cited by 14
Mantzaris, G. J., Roussos, A., Christidou, A., Koilakou, S., Kalantzis, C., Petraki, K., Sfakianakis, M. E., Karagiannidis, A., & Polyzou, P. (2007) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2007.06.002 · Cited by 10
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Metadata
- Authors
- Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-10-30
- Volume
- 2016
- Issue
- 5
- Pages
- CD000067-CD000067
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2102242005
- Cited by
- 402
- References
- 57
- FWCI
- 22.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.